Xenon Pharmaceuticals (NASDAQ:XENE) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference
Xenon Pharmaceuticals (NASDAQ:XENE) had its price target raised by analysts at JPMorgan Chase & Co. from $60.00 to $62.00. They now have an "overweight" rating on the stock.
Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference [Canadian Business Journal (Canada)]
Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]